IP Library Granted Patent US 7,649,096
Granted Patent B2
US 7,649,096 · App. 11/487,766 · Granted Jan 19, 2010

Process for the preparation of a crystalline form of (S)-N [[3-(3-fluoro-4(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide

Assignee: Glenmark Pharmaceuticals Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,649,096
App. No.
11/487,766
Granted
Jan 19, 2010
Kind
B2
Abstract

A process for preparing a crystalline form of linezolid is provided comprising (a) providing a solution comprising linezolid in an organic solvent having a boiling point of less than or equal to about 150° C.; (b) adding an anti-solvent having a boiling point greater than or equal to about 50° C. to the solution; and (c) recovering the crystalline form of linezolid.

Claims (9)

1. A process for preparing a crystalline form of linezolid comprising (a) providing a solution comprising linezolid in an organic solvent wherein the organic solvent is selected from the group consisting of a chlorinated solvent, alcoholic solvent, aliphatic or cyclic ether and mixtures thereof; (b) adding an anti-solvent, wherein the anti-solvent is selected from the group consisting of o-xylene, m-xylene, p-xylene, mesitylene, diphenyl ether, n-heptane and mixture thereof to the solution; and (c) recovering the crystalline form of linezolid; wherein the crystalline form of linezolid is characterized by a powder x-ray diffraction (XRD) pattern substantially in accordance with FIG. 1 and/or an infra red (IR) spectrum substantially in accordance with FIG. 2 .

2. The process of claim 1 , wherein the chlorinated solvent is selected from the group consisting of methylene chloride, ethylene chloride, chloroform, and the mixtures thereof.

3. The process of claim 1 , wherein the alcoholic solvent is selected from the group consisting of methanol, ethanol, isopropanol and mixtures thereof.

4. The process of claim 1 , wherein the aliphatic or cyclic ether solvent is selected from the group consisting of tetrahydrofuran, monoglyme and mixtures thereof.

5. The process of claim 1 , wherein step (c) comprises removing the organic solvent.

6. The process of claim 5 , wherein the organic solvent is removed by evaporation in a rotatory evaporator or under stirring at a temperature of about 30° C. to about 120° C.

7. The process of claim 5 , wherein the organic solvent is removed by evaporation at a temperature of about 50° C. to about 80° C.

8. The process of claim 5 , wherein the organic solvent is removed by evaporation at a temperature of about 60° C. to about 70° C.

9. The process of claim 5 , further comprising filtering the crystalline form of linezolid.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
MERGER Recorded Aug 22, 2019
From: GLENMARK GENERICS LIMITED
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 050156/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2008
From: GLENMARK PHARMACEUTICALS LTD.
To: GLENMARK GENERICS LTD.
Reel/Frame 020733/0397 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2006
From: SIVA KUMAR, BOBBA VENKATA; KULKARNI, PRAVIN BHALCHANDRA; PATEL, GIRISH BANSILAL; PRADHAN, NITIN SHARAD CHANDRA
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 018235/0023 →
Priority Claims (1)
IN 853/2005 · Jul 15, 2005 · national
Continuity (1)
Related Publication 20070015753A1 · Jan 18, 2007